356 related articles for article (PubMed ID: 9106248)
1. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens.
Crespi CL; Penman BW; Steimel DT; Smith T; Yang CS; Sutter TR
Mutagenesis; 1997 Mar; 12(2):83-9. PubMed ID: 9106248
[TBL] [Abstract][Full Text] [Related]
2. Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA: substrate specificity with model substrates and promutagens.
Penman BW; Chen L; Gelboin HV; Gonzalez FJ; Crespi CL
Carcinogenesis; 1994 Sep; 15(9):1931-7. PubMed ID: 7923587
[TBL] [Abstract][Full Text] [Related]
3. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
[TBL] [Abstract][Full Text] [Related]
4. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada T; Gillam EM; Sutter TR; Strickland PT; Guengerich FP; Yamazaki H
Drug Metab Dispos; 1997 May; 25(5):617-22. PubMed ID: 9152602
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin.
Chang TK; Chen J; Yang G; Yeung EY
J Pineal Res; 2010 Jan; 48(1):55-64. PubMed ID: 19919601
[TBL] [Abstract][Full Text] [Related]
6. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin.
Takahashi E; Fujita K; Kamataki T; Arimoto-Kobayashi S; Okamoto K; Negishi T
Mutat Res; 2002 Oct; 508(1-2):147-56. PubMed ID: 12379470
[TBL] [Abstract][Full Text] [Related]
8. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Yamazaki H; Shimada T
Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
[TBL] [Abstract][Full Text] [Related]
9. Induction of CYP1A1 and CYP1B1 in T-47D human breast cancer cells by benzo[a]pyrene is diminished by arsenite.
Spink DC; Katz BH; Hussain MM; Spink BC; Wu SJ; Liu N; Pause R; Kaminsky LS
Drug Metab Dispos; 2002 Mar; 30(3):262-9. PubMed ID: 11854143
[TBL] [Abstract][Full Text] [Related]
10. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences.
Iwanari M; Nakajima M; Kizu R; Hayakawa K; Yokoi T
Arch Toxicol; 2002 Jun; 76(5-6):287-98. PubMed ID: 12107646
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling.
Lo SN; Chang YP; Tsai KC; Chang CY; Wu TS; Ueng YF
Toxicol Appl Pharmacol; 2013 Nov; 272(3):671-80. PubMed ID: 23886934
[TBL] [Abstract][Full Text] [Related]
12. Modulation of rat liver cytochrome P450 by protein restriction assessed by biochemical and bacterial mutagenicity methods [corrected].
Cancino-Badías L; Reyes RE; Nosti R; Pérez I; Dorado V; Caballero S; Soria A; Camacho-Carranza R; Escobar D; Espinosa-Aguirre JJ
Mutagenesis; 2003 Jan; 18(1):95-100. PubMed ID: 12473742
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate.
Chang TK; Waxman DJ
Methods Mol Biol; 2006; 320():85-90. PubMed ID: 16719376
[TBL] [Abstract][Full Text] [Related]
14. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.
Mankowski DC; Lawton MP; Ekins S
Xenobiotica; 2000 Aug; 30(8):745-54. PubMed ID: 11037108
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus.
Henderson MC; Miranda CL; Stevens JF; Deinzer ML; Buhler DR
Xenobiotica; 2000 Mar; 30(3):235-51. PubMed ID: 10752639
[TBL] [Abstract][Full Text] [Related]
16. Effect of alachlor on hepatic cytochrome P450 enzymes in rats.
Hanioka N; Watanabe K; Yoda R; Ando M
Drug Chem Toxicol; 2002 Feb; 25(1):25-37. PubMed ID: 11850968
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.
Chang TK; Chen J; Lee WB
J Pharmacol Exp Ther; 2001 Dec; 299(3):874-82. PubMed ID: 11714871
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cytochrome P-450c-mediated benzo[a]pyrene hydroxylase and ethoxyresorufin O-deethylase by dihydrosafrole.
Kao LR; Wilkinson CF
Xenobiotica; 1987 Jul; 17(7):793-805. PubMed ID: 3660849
[TBL] [Abstract][Full Text] [Related]
19. Interaction of aflatoxin B1 with cytochrome P450 2A5 and its mutants: correlation with metabolic activation and toxicity.
Pelkonen P; Lang MA; Negishi M; Wild CP; Juvonen RO
Chem Res Toxicol; 1997 Jan; 10(1):85-90. PubMed ID: 9074807
[TBL] [Abstract][Full Text] [Related]
20. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
